Erasca, Inc. 8-K

What Happened Erasca, Inc. filed an 8-K on April 21, 2026, announcing it has narrowed the timing for the anticipated Phase 1 monotherapy data readout for its pan‑RAS molecular glue candidate ERAS‑0015 to no later than mid‑May 2026 (previous guidance: first half of 2026). Erasca is evaluating ERAS‑0015 in the AURORAS‑1 Phase 1 trial for patients with RAS‑mutant solid tumors, while licensor Guangzhou Joyo Pharmatech Co., Ltd. (Joyo) is running the JYP0015M101 trial in China for advanced solid tumors with specific RAS mutations.

Key Details

• Filing date: April 21, 2026 (Form 8‑K, Item 8.01 — Other Events).
• New data‑readout timing: no later than mid‑May 2026 (narrowed from “first half of 2026”).
• Trials involved: AURORAS‑1 (Erasca, Phase 1, RAS‑mutant solid tumors) and JYP0015M101 (Joyo, China, advanced solid tumors with specific RAS mutations).
• The filing includes standard forward‑looking statement cautions and references risk factors in Erasca’s 2025 Form 10‑K.

Why It Matters A narrower data‑readout window gives investors a clearer near‑term catalyst for ERAS‑0015, a key clinical program targeting RAS‑mutant cancers. The timing affects when the market can expect initial safety/early efficacy information from Phase 1 monotherapy assessments in both the U.S./global (AURORAS‑1) and China (JYP0015M101) programs. The company’s statement is forward‑looking and subject to risks described in its SEC filings.